FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995808512> ?p ?o ?g. }

• W2995808512 endingPage "609" @default.
• W2995808512 startingPage "597" @default.
• W2995808512 abstract "Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase." @default.
• W2995808512 created "2019-12-26" @default.
• W2995808512 creator A5001562050 @default.
• W2995808512 creator A5003060935 @default.
• W2995808512 creator A5003897511 @default.
• W2995808512 creator A5007286394 @default.
• W2995808512 creator A5010278367 @default.
• W2995808512 creator A5013557141 @default.
• W2995808512 creator A5015491002 @default.
• W2995808512 creator A5018617106 @default.
• W2995808512 creator A5019350144 @default.
• W2995808512 creator A5020748961 @default.
• W2995808512 creator A5024784028 @default.
• W2995808512 creator A5027764647 @default.
• W2995808512 creator A5030502460 @default.
• W2995808512 creator A5031325232 @default.
• W2995808512 creator A5032785430 @default.
• W2995808512 creator A5036380555 @default.
• W2995808512 creator A5039994927 @default.
• W2995808512 creator A5041145711 @default.
• W2995808512 creator A5041410352 @default.
• W2995808512 creator A5047547446 @default.
• W2995808512 creator A5049174232 @default.
• W2995808512 creator A5052268581 @default.
• W2995808512 creator A5053983312 @default.
• W2995808512 creator A5063479774 @default.
• W2995808512 creator A5065638223 @default.
• W2995808512 creator A5067468792 @default.
• W2995808512 creator A5068059897 @default.
• W2995808512 creator A5070245248 @default.
• W2995808512 creator A5075889627 @default.
• W2995808512 creator A5084728559 @default.
• W2995808512 creator A5087559224 @default.
• W2995808512 creator A5088637879 @default.
• W2995808512 date "2020-02-13" @default.
• W2995808512 modified "2023-10-13" @default.
• W2995808512 title "Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer" @default.
• W2995808512 cites W1916687048 @default.
• W2995808512 cites W2000798782 @default.
• W2995808512 cites W2013669698 @default.
• W2995808512 cites W2019607817 @default.
• W2995808512 cites W2062352315 @default.
• W2995808512 cites W2090403447 @default.
• W2995808512 cites W2109924789 @default.
• W2995808512 cites W2114080253 @default.
• W2995808512 cites W2120661754 @default.
• W2995808512 cites W2125401809 @default.
• W2995808512 cites W2127714076 @default.
• W2995808512 cites W2129749518 @default.
• W2995808512 cites W2130735457 @default.
• W2995808512 cites W2134031795 @default.
• W2995808512 cites W2166199281 @default.
• W2995808512 cites W2168814163 @default.
• W2995808512 cites W2571057012 @default.
• W2995808512 cites W2761054293 @default.
• W2995808512 cites W2803163286 @default.
• W2995808512 cites W2833120298 @default.
• W2995808512 cites W2921590809 @default.
• W2995808512 cites W2947217282 @default.
• W2995808512 cites W2947573449 @default.
• W2995808512 cites W4239051461 @default.
• W2995808512 doi "https://doi.org/10.1056/nejmoa1914609" @default.
• W2995808512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31825569" @default.
• W2995808512 hasPublicationYear "2020" @default.
• W2995808512 type Work @default.
• W2995808512 sameAs 2995808512 @default.
• W2995808512 citedByCount "680" @default.
• W2995808512 countsByYear W29958085122020 @default.
• W2995808512 countsByYear W29958085122021 @default.
• W2995808512 countsByYear W29958085122022 @default.
• W2995808512 countsByYear W29958085122023 @default.
• W2995808512 crossrefType "journal-article" @default.
• W2995808512 hasAuthorship W2995808512A5001562050 @default.
• W2995808512 hasAuthorship W2995808512A5003060935 @default.
• W2995808512 hasAuthorship W2995808512A5003897511 @default.
• W2995808512 hasAuthorship W2995808512A5007286394 @default.
• W2995808512 hasAuthorship W2995808512A5010278367 @default.
• W2995808512 hasAuthorship W2995808512A5013557141 @default.
• W2995808512 hasAuthorship W2995808512A5015491002 @default.
• W2995808512 hasAuthorship W2995808512A5018617106 @default.
• W2995808512 hasAuthorship W2995808512A5019350144 @default.
• W2995808512 hasAuthorship W2995808512A5020748961 @default.
• W2995808512 hasAuthorship W2995808512A5024784028 @default.
• W2995808512 hasAuthorship W2995808512A5027764647 @default.
• W2995808512 hasAuthorship W2995808512A5030502460 @default.
• W2995808512 hasAuthorship W2995808512A5031325232 @default.
• W2995808512 hasAuthorship W2995808512A5032785430 @default.
• W2995808512 hasAuthorship W2995808512A5036380555 @default.
• W2995808512 hasAuthorship W2995808512A5039994927 @default.
• W2995808512 hasAuthorship W2995808512A5041145711 @default.
• W2995808512 hasAuthorship W2995808512A5041410352 @default.
• W2995808512 hasAuthorship W2995808512A5047547446 @default.
• W2995808512 hasAuthorship W2995808512A5049174232 @default.
• W2995808512 hasAuthorship W2995808512A5052268581 @default.
• W2995808512 hasAuthorship W2995808512A5053983312 @default.
• W2995808512 hasAuthorship W2995808512A5063479774 @default.
• W2995808512 hasAuthorship W2995808512A5065638223 @default.
• W2995808512 hasAuthorship W2995808512A5067468792 @default.

• next